| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Remodeling | 87 | 2022 | 318 | 17.720 |
Why?
|
| Myocardial Infarction | 56 | 2022 | 807 | 11.500 |
Why?
|
| Matrix Metalloproteinases | 65 | 2022 | 223 | 10.050 |
Why?
|
| Myocardium | 69 | 2022 | 1204 | 8.780 |
Why?
|
| Ventricular Function, Left | 43 | 2022 | 481 | 8.270 |
Why?
|
| Ventricular Dysfunction, Left | 27 | 2021 | 277 | 7.420 |
Why?
|
| Extracellular Matrix | 34 | 2021 | 493 | 6.460 |
Why?
|
| Heart Failure | 39 | 2022 | 1180 | 6.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 31 | 2022 | 85 | 5.450 |
Why?
|
| Heart Ventricles | 17 | 2021 | 738 | 3.280 |
Why?
|
| Matrix Metalloproteinase 14 | 12 | 2014 | 44 | 3.230 |
Why?
|
| Hypertrophy, Left Ventricular | 11 | 2022 | 140 | 3.110 |
Why?
|
| Aprotinin | 9 | 2011 | 55 | 3.050 |
Why?
|
| Myocardial Contraction | 17 | 2018 | 383 | 2.870 |
Why?
|
| Matrix Metalloproteinase 2 | 19 | 2018 | 145 | 2.800 |
Why?
|
| Animals | 129 | 2022 | 20881 | 2.740 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 7 | 2020 | 15 | 2.640 |
Why?
|
| Myocardial Reperfusion Injury | 8 | 2018 | 84 | 2.590 |
Why?
|
| Swine | 37 | 2022 | 672 | 2.500 |
Why?
|
| Cardiopulmonary Bypass | 12 | 2013 | 250 | 2.460 |
Why?
|
| Cytokines | 12 | 2021 | 866 | 2.420 |
Why?
|
| Disease Models, Animal | 44 | 2021 | 2550 | 2.410 |
Why?
|
| Matrix Metalloproteinase 9 | 16 | 2015 | 160 | 2.300 |
Why?
|
| Fibroblasts | 16 | 2020 | 902 | 2.260 |
Why?
|
| Heart Diseases | 6 | 2021 | 276 | 1.990 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 12 | 2021 | 59 | 1.970 |
Why?
|
| Antifibrinolytic Agents | 5 | 2011 | 52 | 1.720 |
Why?
|
| Cardiac Surgical Procedures | 8 | 2013 | 450 | 1.680 |
Why?
|
| Stroke Volume | 19 | 2022 | 586 | 1.660 |
Why?
|
| Serine Proteinase Inhibitors | 5 | 2011 | 48 | 1.660 |
Why?
|
| Hemodynamics | 15 | 2020 | 705 | 1.540 |
Why?
|
| Aortic Aneurysm, Thoracic | 15 | 2013 | 134 | 1.500 |
Why?
|
| Echocardiography | 16 | 2020 | 515 | 1.500 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2021 | 89 | 1.450 |
Why?
|
| Heart | 11 | 2022 | 850 | 1.390 |
Why?
|
| Cardiomyopathy, Dilated | 6 | 2012 | 106 | 1.370 |
Why?
|
| Fibrosis | 13 | 2020 | 371 | 1.370 |
Why?
|
| Heart Arrest, Induced | 5 | 2008 | 52 | 1.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2021 | 626 | 1.340 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 11 | 2010 | 59 | 1.300 |
Why?
|
| Humans | 103 | 2022 | 68618 | 1.240 |
Why?
|
| Coronary Artery Bypass | 6 | 2011 | 218 | 1.210 |
Why?
|
| Collagen | 18 | 2020 | 636 | 1.200 |
Why?
|
| Signal Transduction | 18 | 2014 | 2689 | 1.170 |
Why?
|
| Fibrinolysin | 5 | 2011 | 33 | 1.160 |
Why?
|
| Ventricular Pressure | 7 | 2014 | 82 | 1.160 |
Why?
|
| Male | 75 | 2021 | 37321 | 1.160 |
Why?
|
| Biocompatible Materials | 3 | 2016 | 247 | 1.130 |
Why?
|
| Time Factors | 26 | 2021 | 4655 | 1.110 |
Why?
|
| Mice | 45 | 2022 | 8474 | 1.110 |
Why?
|
| Tranexamic Acid | 3 | 2011 | 37 | 1.080 |
Why?
|
| Caspase Inhibitors | 4 | 2010 | 36 | 1.070 |
Why?
|
| Myocytes, Cardiac | 10 | 2016 | 442 | 1.040 |
Why?
|
| Disease Progression | 19 | 2021 | 1038 | 1.040 |
Why?
|
| Biomarkers | 13 | 2022 | 1593 | 1.040 |
Why?
|
| Reperfusion Injury | 3 | 2017 | 320 | 1.040 |
Why?
|
| Microdialysis | 9 | 2012 | 147 | 1.020 |
Why?
|
| Hemostatics | 3 | 2011 | 47 | 1.000 |
Why?
|
| Aging | 7 | 2019 | 911 | 0.990 |
Why?
|
| Mice, Transgenic | 15 | 2020 | 1033 | 0.960 |
Why?
|
| Endothelin A Receptor Antagonists | 3 | 2010 | 22 | 0.960 |
Why?
|
| Gene Targeting | 3 | 2014 | 58 | 0.890 |
Why?
|
| Female | 59 | 2022 | 38074 | 0.880 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 82 | 0.880 |
Why?
|
| Promoter Regions, Genetic | 6 | 2012 | 615 | 0.870 |
Why?
|
| Endothelins | 4 | 2008 | 57 | 0.870 |
Why?
|
| Models, Cardiovascular | 5 | 2020 | 133 | 0.870 |
Why?
|
| Myocardial Ischemia | 4 | 2020 | 172 | 0.840 |
Why?
|
| Inflammation Mediators | 4 | 2016 | 244 | 0.830 |
Why?
|
| Fibrillar Collagens | 5 | 2021 | 49 | 0.830 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2022 | 119 | 0.830 |
Why?
|
| Atrial Remodeling | 1 | 2022 | 1 | 0.820 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 249 | 0.800 |
Why?
|
| Circulating MicroRNA | 2 | 2019 | 9 | 0.800 |
Why?
|
| Methylprednisolone | 2 | 2013 | 99 | 0.800 |
Why?
|
| Aorta | 4 | 2021 | 316 | 0.790 |
Why?
|
| Enzyme Inhibitors | 5 | 2005 | 659 | 0.770 |
Why?
|
| Peptide Fragments | 3 | 2020 | 483 | 0.760 |
Why?
|
| Sarcoidosis | 1 | 2021 | 77 | 0.750 |
Why?
|
| Renin-Angiotensin System | 3 | 2018 | 79 | 0.750 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 562 | 0.740 |
Why?
|
| Transcriptome | 3 | 2019 | 164 | 0.740 |
Why?
|
| Aorta, Thoracic | 11 | 2011 | 211 | 0.730 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 160 | 0.730 |
Why?
|
| Oligopeptides | 4 | 2010 | 152 | 0.730 |
Why?
|
| Glucocorticoids | 2 | 2013 | 222 | 0.730 |
Why?
|
| Isoxazoles | 3 | 2010 | 22 | 0.720 |
Why?
|
| MicroRNAs | 4 | 2013 | 447 | 0.720 |
Why?
|
| Matrix Metalloproteinase 8 | 3 | 2017 | 22 | 0.720 |
Why?
|
| Gene Expression Regulation | 9 | 2020 | 1293 | 0.700 |
Why?
|
| Thiophenes | 3 | 2010 | 76 | 0.700 |
Why?
|
| Myofibroblasts | 3 | 2018 | 60 | 0.700 |
Why?
|
| Diastole | 6 | 2021 | 161 | 0.690 |
Why?
|
| Isoenzymes | 6 | 2007 | 308 | 0.690 |
Why?
|
| Aminocaproic Acid | 2 | 2010 | 12 | 0.670 |
Why?
|
| Gene Deletion | 6 | 2021 | 235 | 0.670 |
Why?
|
| Hydroxamic Acids | 3 | 2005 | 84 | 0.660 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 27 | 0.650 |
Why?
|
| Anthracyclines | 1 | 2018 | 9 | 0.640 |
Why?
|
| C-Reactive Protein | 2 | 2018 | 180 | 0.630 |
Why?
|
| Enzyme Induction | 6 | 2012 | 119 | 0.620 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 88 | 0.620 |
Why?
|
| Middle Aged | 35 | 2021 | 21147 | 0.620 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 82 | 0.610 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2018 | 155 | 0.610 |
Why?
|
| Neoplasms | 2 | 2019 | 1667 | 0.600 |
Why?
|
| Drug Carriers | 1 | 2018 | 90 | 0.600 |
Why?
|
| Heart Conduction System | 2 | 2010 | 119 | 0.590 |
Why?
|
| Electric Stimulation | 1 | 2018 | 218 | 0.580 |
Why?
|
| Enzyme Activation | 14 | 2010 | 791 | 0.580 |
Why?
|
| Endothelin-1 | 5 | 2010 | 122 | 0.570 |
Why?
|
| Cardiovascular Physiological Phenomena | 3 | 2019 | 40 | 0.570 |
Why?
|
| Protein Kinase C | 3 | 2007 | 270 | 0.570 |
Why?
|
| Heart Valve Diseases | 3 | 2015 | 123 | 0.570 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 206 | 0.570 |
Why?
|
| Sheep | 9 | 2011 | 128 | 0.560 |
Why?
|
| Aortic Valve | 3 | 2015 | 249 | 0.560 |
Why?
|
| Protease Inhibitors | 3 | 2006 | 76 | 0.550 |
Why?
|
| Cardiomegaly | 4 | 2014 | 213 | 0.550 |
Why?
|
| Postoperative Period | 6 | 2018 | 238 | 0.540 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 940 | 0.540 |
Why?
|
| Gene Transfer Techniques | 2 | 2014 | 173 | 0.540 |
Why?
|
| Heart Function Tests | 1 | 2015 | 33 | 0.520 |
Why?
|
| RNA | 2 | 2014 | 171 | 0.520 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 58 | 0.520 |
Why?
|
| Recombinant Proteins | 6 | 2018 | 742 | 0.510 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 167 | 0.500 |
Why?
|
| Aged | 22 | 2021 | 14862 | 0.490 |
Why?
|
| Blood Pressure | 8 | 2012 | 1451 | 0.490 |
Why?
|
| Preoperative Care | 3 | 2013 | 275 | 0.490 |
Why?
|
| Homeostasis | 3 | 2011 | 291 | 0.480 |
Why?
|
| Postoperative Hemorrhage | 2 | 2011 | 69 | 0.480 |
Why?
|
| Mice, Inbred C57BL | 13 | 2021 | 2791 | 0.480 |
Why?
|
| Postoperative Complications | 5 | 2011 | 1615 | 0.470 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 17 | 0.470 |
Why?
|
| Case-Control Studies | 5 | 2021 | 1553 | 0.460 |
Why?
|
| Hydrogels | 3 | 2022 | 54 | 0.460 |
Why?
|
| Mice, Knockout | 8 | 2022 | 1692 | 0.460 |
Why?
|
| Gene Expression Regulation, Enzymologic | 6 | 2013 | 282 | 0.460 |
Why?
|
| RNA, Messenger | 8 | 2020 | 1664 | 0.460 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 79 | 0.460 |
Why?
|
| Caspases | 3 | 2010 | 194 | 0.460 |
Why?
|
| Coronary Circulation | 3 | 2019 | 136 | 0.450 |
Why?
|
| Random Allocation | 7 | 2010 | 442 | 0.450 |
Why?
|
| Inflammation | 3 | 2021 | 1030 | 0.450 |
Why?
|
| Leukocytes | 2 | 2004 | 99 | 0.450 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 5 | 2010 | 20 | 0.450 |
Why?
|
| Basigin | 2 | 2016 | 53 | 0.440 |
Why?
|
| Fibrinolysis | 2 | 2010 | 55 | 0.440 |
Why?
|
| Heart Rupture | 1 | 2013 | 1 | 0.440 |
Why?
|
| Matrix Metalloproteinases, Secreted | 1 | 2013 | 1 | 0.440 |
Why?
|
| Genetic Therapy | 2 | 2012 | 291 | 0.440 |
Why?
|
| Metalloendopeptidases | 4 | 2005 | 67 | 0.430 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2005 | 116 | 0.430 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2010 | 73 | 0.430 |
Why?
|
| Macrophage Activation | 1 | 2013 | 75 | 0.430 |
Why?
|
| Prognosis | 6 | 2020 | 2093 | 0.420 |
Why?
|
| Cells, Cultured | 8 | 2020 | 2673 | 0.420 |
Why?
|
| Sus scrofa | 5 | 2020 | 74 | 0.420 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2012 | 14 | 0.410 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2012 | 74 | 0.410 |
Why?
|
| Treatment Outcome | 11 | 2022 | 7029 | 0.400 |
Why?
|
| Chemokine CCL7 | 1 | 2011 | 1 | 0.400 |
Why?
|
| Enterovirus B, Human | 1 | 2011 | 3 | 0.400 |
Why?
|
| Coxsackievirus Infections | 1 | 2011 | 2 | 0.400 |
Why?
|
| Peptides | 3 | 2006 | 455 | 0.400 |
Why?
|
| Durapatite | 1 | 2011 | 33 | 0.390 |
Why?
|
| Plasma | 1 | 2011 | 58 | 0.390 |
Why?
|
| Microspheres | 1 | 2011 | 59 | 0.390 |
Why?
|
| Kidney | 5 | 2011 | 945 | 0.390 |
Why?
|
| Myocardial Reperfusion | 2 | 2008 | 32 | 0.390 |
Why?
|
| Myocarditis | 1 | 2011 | 49 | 0.390 |
Why?
|
| Erythrocytes | 1 | 2011 | 137 | 0.380 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2010 | 239 | 0.380 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 2011 | 174 | 0.380 |
Why?
|
| Heart Failure, Diastolic | 1 | 2011 | 14 | 0.380 |
Why?
|
| Age Factors | 5 | 2020 | 1864 | 0.380 |
Why?
|
| Animals, Newborn | 2 | 2016 | 396 | 0.370 |
Why?
|
| Risk Factors | 8 | 2018 | 5731 | 0.370 |
Why?
|
| Endotoxins | 1 | 2010 | 76 | 0.370 |
Why?
|
| Heart Septal Defects | 1 | 2010 | 27 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2011 | 1745 | 0.360 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 83 | 0.350 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 301 | 0.350 |
Why?
|
| Heart Valve Prosthesis | 1 | 2011 | 222 | 0.350 |
Why?
|
| Models, Animal | 5 | 2020 | 252 | 0.350 |
Why?
|
| Prospective Studies | 6 | 2021 | 3705 | 0.340 |
Why?
|
| Heart Defects, Congenital | 2 | 2011 | 596 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2011 | 164 | 0.340 |
Why?
|
| Immunohistochemistry | 7 | 2011 | 1174 | 0.340 |
Why?
|
| Aortic Valve Stenosis | 1 | 2011 | 177 | 0.340 |
Why?
|
| Phenotype | 7 | 2020 | 947 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.330 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 201 | 0.330 |
Why?
|
| Heart-Assist Devices | 3 | 2009 | 221 | 0.330 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 371 | 0.320 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2009 | 63 | 0.320 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 27 | 0.320 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 1506 | 0.320 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 147 | 0.320 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 498 | 0.310 |
Why?
|
| Dogs | 5 | 2011 | 490 | 0.310 |
Why?
|
| Rewarming | 2 | 2004 | 11 | 0.310 |
Why?
|
| Cardioplegic Solutions | 2 | 2004 | 15 | 0.310 |
Why?
|
| Extracellular Space | 2 | 2011 | 121 | 0.300 |
Why?
|
| Coronary Vessels | 4 | 2017 | 313 | 0.290 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2007 | 15 | 0.290 |
Why?
|
| Pulmonary Artery | 5 | 2013 | 323 | 0.290 |
Why?
|
| Mass Screening | 1 | 2013 | 843 | 0.290 |
Why?
|
| Immunoblotting | 4 | 2014 | 254 | 0.280 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2009 | 80 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 5 | 2010 | 384 | 0.280 |
Why?
|
| Up-Regulation | 5 | 2014 | 682 | 0.280 |
Why?
|
| Injections | 2 | 2020 | 119 | 0.280 |
Why?
|
| Oxidative Stress | 3 | 2016 | 718 | 0.270 |
Why?
|
| Muscle Cells | 3 | 2008 | 30 | 0.270 |
Why?
|
| Metalloproteases | 1 | 2006 | 9 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 2223 | 0.260 |
Why?
|
| Electrocardiography | 5 | 2013 | 601 | 0.260 |
Why?
|
| Connexin 43 | 1 | 2006 | 62 | 0.260 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1465 | 0.260 |
Why?
|
| Apoptosis | 7 | 2014 | 1641 | 0.260 |
Why?
|
| Neovascularization, Physiologic | 2 | 2010 | 164 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2021 | 32 | 0.250 |
Why?
|
| Risk Assessment | 3 | 2021 | 2007 | 0.250 |
Why?
|
| Analysis of Variance | 4 | 2011 | 1040 | 0.250 |
Why?
|
| Extracellular Matrix Proteins | 5 | 2011 | 144 | 0.250 |
Why?
|
| Thrombospondins | 1 | 2004 | 5 | 0.240 |
Why?
|
| Heart Rate | 4 | 2010 | 568 | 0.240 |
Why?
|
| Hemofiltration | 1 | 2004 | 7 | 0.240 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2004 | 24 | 0.240 |
Why?
|
| Troponin | 2 | 2017 | 25 | 0.240 |
Why?
|
| Myocardial Revascularization | 1 | 2004 | 56 | 0.240 |
Why?
|
| Protein Transport | 1 | 2005 | 280 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 212 | 0.230 |
Why?
|
| Creatine Kinase | 1 | 2003 | 46 | 0.230 |
Why?
|
| Integrins | 3 | 2014 | 115 | 0.220 |
Why?
|
| Neurotransmitter Agents | 3 | 2012 | 102 | 0.220 |
Why?
|
| Area Under Curve | 3 | 2010 | 238 | 0.220 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2017 | 101 | 0.220 |
Why?
|
| Exercise | 2 | 2019 | 658 | 0.220 |
Why?
|
| Cyclosporine | 2 | 2014 | 121 | 0.220 |
Why?
|
| Extracorporeal Circulation | 1 | 2003 | 26 | 0.220 |
Why?
|
| Aortic Diseases | 2 | 2016 | 113 | 0.220 |
Why?
|
| Coronary Disease | 1 | 2005 | 358 | 0.220 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 1083 | 0.220 |
Why?
|
| Alcohols | 1 | 2002 | 13 | 0.220 |
Why?
|
| Dilatation, Pathologic | 5 | 2011 | 58 | 0.210 |
Why?
|
| Catheter Ablation | 1 | 2005 | 229 | 0.210 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2002 | 10 | 0.210 |
Why?
|
| Genetic Vectors | 2 | 2014 | 312 | 0.210 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2002 | 153 | 0.210 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 209 | 0.200 |
Why?
|
| Smad2 Protein | 2 | 2012 | 42 | 0.200 |
Why?
|
| In Vitro Techniques | 4 | 2010 | 765 | 0.200 |
Why?
|
| Infant, Newborn | 3 | 2013 | 2455 | 0.200 |
Why?
|
| Actins | 3 | 2010 | 249 | 0.200 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 546 | 0.200 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2021 | 42 | 0.200 |
Why?
|
| Blotting, Western | 3 | 2012 | 954 | 0.190 |
Why?
|
| Evaluation Studies as Topic | 1 | 2021 | 219 | 0.190 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2012 | 56 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 81 | 0.190 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 114 | 0.190 |
Why?
|
| Latent TGF-beta Binding Proteins | 2 | 2011 | 14 | 0.190 |
Why?
|
| Calcium | 2 | 2008 | 929 | 0.190 |
Why?
|
| Hypertension | 4 | 2012 | 1535 | 0.190 |
Why?
|
| Microscopy, Confocal | 3 | 2007 | 337 | 0.180 |
Why?
|
| Lysine | 2 | 2011 | 96 | 0.180 |
Why?
|
| Body Size | 2 | 2011 | 39 | 0.180 |
Why?
|
| Protein Domains | 1 | 2020 | 74 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 219 | 0.180 |
Why?
|
| Quadriceps Muscle | 2 | 2010 | 23 | 0.180 |
Why?
|
| Systole | 4 | 2010 | 149 | 0.180 |
Why?
|
| Proteolysis | 1 | 2020 | 97 | 0.180 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 9 | 0.180 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2010 | 112 | 0.170 |
Why?
|
| Cardiology | 2 | 2012 | 140 | 0.170 |
Why?
|
| Elasticity | 3 | 2009 | 103 | 0.170 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1738 | 0.170 |
Why?
|
| Cell Membrane | 3 | 2007 | 525 | 0.170 |
Why?
|
| Collagen Type I | 2 | 2014 | 175 | 0.170 |
Why?
|
| Infant | 3 | 2010 | 2891 | 0.170 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 334 | 0.170 |
Why?
|
| Calcium Chloride | 4 | 2010 | 38 | 0.170 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 31 | 0.170 |
Why?
|
| Cardiotonic Agents | 3 | 2010 | 71 | 0.170 |
Why?
|
| Ultrasonography | 4 | 2011 | 453 | 0.170 |
Why?
|
| Probability | 2 | 2010 | 245 | 0.160 |
Why?
|
| Stem Cells | 2 | 2011 | 248 | 0.160 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 12 | 0.160 |
Why?
|
| Recovery of Function | 2 | 2014 | 506 | 0.160 |
Why?
|
| Gelatinases | 2 | 2010 | 12 | 0.160 |
Why?
|
| Angiotensin II | 6 | 2016 | 220 | 0.160 |
Why?
|
| Child | 3 | 2018 | 6405 | 0.160 |
Why?
|
| Ethanol | 1 | 2005 | 893 | 0.160 |
Why?
|
| beta-Galactosidase | 2 | 2010 | 88 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2018 | 87 | 0.160 |
Why?
|
| Fluorescent Dyes | 2 | 2011 | 191 | 0.160 |
Why?
|
| Drug Compounding | 1 | 2018 | 34 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2011 | 330 | 0.160 |
Why?
|
| Cardiac Output, Low | 2 | 2011 | 52 | 0.150 |
Why?
|
| Ligation | 2 | 2010 | 83 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 120 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 237 | 0.150 |
Why?
|
| Kinetics | 3 | 2009 | 1047 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2012 | 710 | 0.150 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2017 | 27 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 514 | 0.150 |
Why?
|
| Gene Expression | 3 | 2010 | 770 | 0.150 |
Why?
|
| Reference Values | 3 | 2008 | 579 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2011 | 689 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.150 |
Why?
|
| Troponin I | 2 | 2010 | 34 | 0.150 |
Why?
|
| Phosphorylation | 2 | 2012 | 1200 | 0.150 |
Why?
|
| Drug Delivery Systems | 2 | 2013 | 236 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2018 | 320 | 0.140 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 3 | 2006 | 11 | 0.140 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2022 | 137 | 0.140 |
Why?
|
| Adolescent | 3 | 2018 | 8912 | 0.140 |
Why?
|
| Receptors for Activated C Kinase | 2 | 2006 | 5 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 2077 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1851 | 0.130 |
Why?
|
| Adult | 9 | 2019 | 21403 | 0.130 |
Why?
|
| Length of Stay | 2 | 2013 | 780 | 0.130 |
Why?
|
| South Carolina | 2 | 2013 | 2752 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 1753 | 0.130 |
Why?
|
| Histone Deacetylase 1 | 1 | 2015 | 32 | 0.120 |
Why?
|
| Electric Countershock | 2 | 2013 | 130 | 0.120 |
Why?
|
| Cell Survival | 2 | 2010 | 901 | 0.120 |
Why?
|
| Hyperkalemia | 2 | 2004 | 21 | 0.120 |
Why?
|
| Liver | 2 | 2010 | 1118 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 848 | 0.120 |
Why?
|
| Action Potentials | 1 | 2015 | 223 | 0.120 |
Why?
|
| Discoidin Domain Receptors | 1 | 2014 | 16 | 0.120 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 61 | 0.120 |
Why?
|
| Receptors, Mitogen | 1 | 2014 | 23 | 0.120 |
Why?
|
| Matrix Metalloproteinase 13 | 2 | 2011 | 24 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 116 | 0.120 |
Why?
|
| Brain | 2 | 2019 | 2176 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2010 | 3187 | 0.110 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 200 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 100 | 0.110 |
Why?
|
| Arteriovenous Malformations | 1 | 2013 | 34 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2011 | 7277 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2014 | 295 | 0.110 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 12 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2013 | 144 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.110 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 81 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 113 | 0.110 |
Why?
|
| Species Specificity | 2 | 2012 | 303 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 376 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2013 | 234 | 0.100 |
Why?
|
| Caspase 3 | 2 | 2010 | 233 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 113 | 0.100 |
Why?
|
| Macrophages | 2 | 2006 | 647 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 567 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2013 | 159 | 0.100 |
Why?
|
| Factor VIIa | 1 | 2011 | 25 | 0.100 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 21 | 0.100 |
Why?
|
| Estrogens | 1 | 2013 | 173 | 0.100 |
Why?
|
| Contraindications | 1 | 2011 | 52 | 0.100 |
Why?
|
| Veterans | 1 | 2019 | 904 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2011 | 60 | 0.100 |
Why?
|
| Survival | 1 | 2011 | 22 | 0.100 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 72 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2011 | 133 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2016 | 866 | 0.090 |
Why?
|
| Vasodilation | 1 | 2011 | 85 | 0.090 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 168 | 0.090 |
Why?
|
| Intraoperative Care | 1 | 2011 | 91 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 76 | 0.090 |
Why?
|
| Transfection | 1 | 2012 | 782 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2013 | 295 | 0.090 |
Why?
|
| Machine Learning | 2 | 2022 | 170 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2011 | 190 | 0.090 |
Why?
|
| Atrioventricular Node | 1 | 2010 | 39 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 172 | 0.090 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2010 | 27 | 0.090 |
Why?
|
| Thoracotomy | 1 | 2010 | 25 | 0.090 |
Why?
|
| Peptide Hydrolases | 2 | 2008 | 82 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2011 | 163 | 0.090 |
Why?
|
| Enzyme Precursors | 1 | 2010 | 27 | 0.090 |
Why?
|
| Biophysics | 1 | 2010 | 41 | 0.090 |
Why?
|
| Myosins | 1 | 2010 | 34 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 384 | 0.090 |
Why?
|
| Heme Oxygenase-1 | 1 | 2010 | 40 | 0.090 |
Why?
|
| Chemokines | 1 | 2010 | 119 | 0.090 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2010 | 50 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.090 |
Why?
|
| Reperfusion | 1 | 2010 | 78 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 536 | 0.090 |
Why?
|
| Marfan Syndrome | 2 | 2008 | 42 | 0.090 |
Why?
|
| Prosthesis Design | 1 | 2011 | 301 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1034 | 0.090 |
Why?
|
| Cell Death | 1 | 2010 | 329 | 0.080 |
Why?
|
| Glycation End Products, Advanced | 1 | 2010 | 125 | 0.080 |
Why?
|
| Cell Division | 1 | 2010 | 541 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2010 | 157 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2010 | 249 | 0.080 |
Why?
|
| Dipeptides | 1 | 2009 | 89 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2008 | 25 | 0.080 |
Why?
|
| Tachycardia, Ventricular | 1 | 2010 | 153 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2009 | 81 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2012 | 310 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 232 | 0.080 |
Why?
|
| Peroxidase | 1 | 2008 | 40 | 0.080 |
Why?
|
| Microinjections | 1 | 2008 | 130 | 0.080 |
Why?
|
| Rats | 5 | 2016 | 5300 | 0.080 |
Why?
|
| Calpain | 1 | 2009 | 205 | 0.080 |
Why?
|
| Autophagy | 1 | 2010 | 208 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 181 | 0.080 |
Why?
|
| Proteomics | 1 | 2010 | 246 | 0.080 |
Why?
|
| Endothelin B Receptor Antagonists | 1 | 2007 | 11 | 0.080 |
Why?
|
| Threonine | 1 | 2007 | 47 | 0.080 |
Why?
|
| Hypertrophy | 1 | 2008 | 89 | 0.080 |
Why?
|
| Interleukins | 1 | 2008 | 79 | 0.080 |
Why?
|
| Aorta, Abdominal | 1 | 2008 | 97 | 0.080 |
Why?
|
| Receptor, Endothelin B | 1 | 2007 | 34 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 396 | 0.080 |
Why?
|
| Hemostasis | 1 | 2007 | 32 | 0.070 |
Why?
|
| Peptides, Cyclic | 1 | 2007 | 35 | 0.070 |
Why?
|
| Polyribosomes | 1 | 2007 | 24 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 132 | 0.070 |
Why?
|
| Intracellular Space | 1 | 2007 | 42 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2007 | 71 | 0.070 |
Why?
|
| Acetylcysteine | 1 | 2010 | 296 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2324 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2008 | 129 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 1342 | 0.070 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2008 | 99 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 5717 | 0.070 |
Why?
|
| Defibrillators, Implantable | 1 | 2010 | 329 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2008 | 139 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 475 | 0.070 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2007 | 181 | 0.070 |
Why?
|
| Protein Kinase C beta | 1 | 2006 | 19 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2007 | 179 | 0.070 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2006 | 28 | 0.070 |
Why?
|
| Aortic Aneurysm | 1 | 2007 | 77 | 0.070 |
Why?
|
| Heart Block | 1 | 2006 | 49 | 0.070 |
Why?
|
| Gap Junctions | 1 | 2006 | 29 | 0.070 |
Why?
|
| Electric Conductivity | 1 | 2006 | 87 | 0.070 |
Why?
|
| Laminin | 1 | 2006 | 62 | 0.070 |
Why?
|
| Cell Communication | 1 | 2006 | 116 | 0.070 |
Why?
|
| Fibronectins | 1 | 2006 | 130 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 166 | 0.060 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2005 | 31 | 0.060 |
Why?
|
| Biopsy | 1 | 2007 | 540 | 0.060 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2005 | 20 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 248 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 652 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 92 | 0.060 |
Why?
|
| Endosomes | 1 | 2005 | 45 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 95 | 0.060 |
Why?
|
| Temperature | 1 | 2006 | 341 | 0.060 |
Why?
|
| Heart Septum | 1 | 2005 | 84 | 0.060 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 92 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 629 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2006 | 152 | 0.060 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2004 | 22 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 92 | 0.060 |
Why?
|
| Thrombolytic Therapy | 1 | 2006 | 233 | 0.060 |
Why?
|
| Cell Separation | 1 | 2004 | 132 | 0.060 |
Why?
|
| Isotonic Solutions | 1 | 2004 | 25 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 714 | 0.060 |
Why?
|
| Pressure | 1 | 2005 | 252 | 0.060 |
Why?
|
| Hematologic Tests | 1 | 2004 | 24 | 0.060 |
Why?
|
| Electrolytes | 1 | 2004 | 47 | 0.060 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 20 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2003 | 30 | 0.060 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2003 | 22 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 1447 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 532 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 93 | 0.060 |
Why?
|
| Biological Transport | 1 | 2003 | 210 | 0.060 |
Why?
|
| Protein Binding | 1 | 2006 | 1027 | 0.050 |
Why?
|
| Filtration | 1 | 2003 | 61 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2010 | 1330 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2004 | 215 | 0.050 |
Why?
|
| Depression, Chemical | 1 | 2002 | 29 | 0.050 |
Why?
|
| Adrenomedullin | 1 | 2002 | 27 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 137 | 0.050 |
Why?
|
| Lung | 1 | 2007 | 849 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2022 | 67 | 0.050 |
Why?
|
| Xanthines | 1 | 2002 | 17 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2003 | 100 | 0.050 |
Why?
|
| Piperazines | 1 | 2003 | 206 | 0.050 |
Why?
|
| Organ Size | 3 | 2011 | 242 | 0.050 |
Why?
|
| Feedback, Physiological | 1 | 2002 | 38 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 507 | 0.050 |
Why?
|
| Wound Healing | 1 | 2003 | 260 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 1173 | 0.050 |
Why?
|
| Antibodies | 1 | 2002 | 241 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2004 | 1174 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2006 | 2358 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2020 | 55 | 0.040 |
Why?
|
| Physical Endurance | 1 | 2019 | 38 | 0.040 |
Why?
|
| Heart Atria | 2 | 2013 | 206 | 0.040 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 208 | 0.040 |
Why?
|
| Disease Susceptibility | 2 | 2011 | 179 | 0.040 |
Why?
|
| Exercise Test | 1 | 2019 | 242 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 189 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2011 | 186 | 0.040 |
Why?
|
| Pregnancy | 1 | 2022 | 2334 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2009 | 167 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3259 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 27 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 94 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 140 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 175 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 371 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 331 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 104 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 411 | 0.030 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cats | 2 | 2003 | 292 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 168 | 0.030 |
Why?
|
| Elastic Tissue | 1 | 2011 | 28 | 0.020 |
Why?
|
| Thallium Radioisotopes | 1 | 2011 | 13 | 0.020 |
Why?
|
| Mutation | 2 | 2008 | 1213 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 83 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 948 | 0.020 |
Why?
|
| Microbubbles | 1 | 2010 | 8 | 0.020 |
Why?
|
| Colloids | 1 | 2010 | 43 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1046 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2010 | 138 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2010 | 58 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 201 | 0.020 |
Why?
|
| Gold | 1 | 2010 | 76 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 87 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2010 | 95 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 215 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 363 | 0.020 |
Why?
|
| Lac Operon | 1 | 2009 | 54 | 0.020 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2008 | 4 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2008 | 25 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2009 | 191 | 0.020 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2008 | 13 | 0.020 |
Why?
|
| Elastin | 1 | 2009 | 116 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 509 | 0.020 |
Why?
|
| Walking | 1 | 2010 | 241 | 0.020 |
Why?
|
| Aldosterone | 1 | 2008 | 51 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 54 | 0.020 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2008 | 38 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 4848 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 786 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 381 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 36 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 216 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 595 | 0.020 |
Why?
|
| Fibrillins | 1 | 2006 | 24 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2007 | 166 | 0.020 |
Why?
|
| Collagenases | 1 | 2006 | 34 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 102 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 729 | 0.020 |
Why?
|
| Mitochondria | 1 | 2010 | 643 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 786 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 1196 | 0.020 |
Why?
|
| Cell Size | 1 | 2004 | 76 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 258 | 0.010 |
Why?
|
| Radio Waves | 1 | 2003 | 21 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2004 | 156 | 0.010 |
Why?
|
| Regeneration | 1 | 2004 | 105 | 0.010 |
Why?
|
| Angiotensin I | 1 | 2003 | 24 | 0.010 |
Why?
|
| Angiotensinogen | 1 | 2003 | 18 | 0.010 |
Why?
|
| Losartan | 1 | 2003 | 45 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 38 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2003 | 31 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2003 | 59 | 0.010 |
Why?
|
| Forecasting | 1 | 2004 | 277 | 0.010 |
Why?
|
| Renin | 1 | 2003 | 96 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 2002 | 30 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 2002 | 33 | 0.010 |
Why?
|
| Constriction | 1 | 2002 | 37 | 0.010 |
Why?
|
| Viscosity | 1 | 2002 | 72 | 0.010 |
Why?
|
| Quality of Life | 1 | 2010 | 1515 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2002 | 236 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 554 | 0.010 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2002 | 117 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 377 | 0.010 |
Why?
|